title: Consumption of psychotropic medication in the elderly: a re-evaluation of its effect on cognitive performance.
abstract: BACKGROUND
  There have been few general population studies of the effects of psychotropic treatment on cognitive functioning in the elderly. Current evidence based on studies with numerous procedural shortenings supports the notion of the detrimental effect.
  
  
  OBJECTIVE
  To examine changes in a wide range of specific cognitive abilities across time in a general population sample in order to establish a relationship between psychotropic drug use and cognitive performance, and to estimate to what extent such cognitive changes may be attributable to psychotropic use or other factors, notably age and co-morbidity.
  
  
  METHODS
  We analysed the data from the Eugeria longitudinal study of cerebral ageing. Three hundred and seventy two subjects (263 female and 109 male) were visited at their place of residence and given a computerized cognitive examination. Depressive symptomatology and depressive episodes were defined according to ICD-9 criterias and medication use were established. Four categories of psychotropic consumers was differentiated. Using a logistic regression model, comparisons were made between consumers and non-consumers.
  
  
  RESULTS
  A significant positive effect in chronic consumers was found on tests of secondary memory (delayed verbal recall: Odds Ratio (OR)=1.22; 95% Confidence Intervals (CI) [1.04-1.43]; p=0.013) and this effect is principally attributable to antidepressants with significant effects being shown for both verbal (OR=1.59; 95%CI [1.18-2.14]; p=0.002) and visual recall (OR=1.51; 95%CI [1.05-2.16]; p=0.025). No effect is found for benzodiazepines.
  
  
  CONCLUSIONS
  Contrary to the common belief that psychotropic drug use has a detrimental effect on cognitive function of elderly people, even long term use is seen to be benign. We attest to the positive effects of antidepressant therapy on secondary memory.
authors.affiliation: Sherbrooke Geriatric University Institute, Sherbrooke, Quebec, Canada. jallard.iugs@ssss.gouv.qc.ca
authors.forename: Jacques
authors.initials: J
authors.lastname: Allard
authors.forename: Sylvaine
authors.initials: S
authors.lastname: Artero
authors.forename: Karen
authors.initials: K
authors.lastname: Ritchie
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000523:psychology; D000928:Antidepressive Agents / Q000009:adverse effects; D001569:Benzodiazepines / Q000009:adverse effects; D003072:Cognition Disorders / Q000139:chemically induced*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008568:Memory / Q000187:drug effects; D011939:Mental Recall / Q000187:drug effects; D009483:Neuropsychological Tests; D011619:Psychotropic Drugs / Q000009:adverse effects*; D011930:Reaction Time / Q000187:drug effects; D012044:Regression Analysis; D012307:Risk Factors
chemical_list: D000928:Antidepressive Agents; D011619:Psychotropic Drugs; D001569:Benzodiazepines